Pharmacokinetics of pazopanib administered in combination with bevacizumab

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 6, 2014, Pages 1189-1196

  Imbs, Diane Charlotte ^a   Négrier, Sylvie ^b   Cassier, Philippe ^b   Hollebecque, Antoine ^c   Varga, Andrea ^c   Blanc, Ellen ^b   Lafont, Thierry ^a   Escudier, Bernard ^c   Soria, Jean Charles ^c   Pérol, David ^b   Chatelut, Etienne ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b CENTRE LÉON BÉRARD   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Drug interaction; Pharmacokinetic pharmacodynamic relationships; Population pharmacokinetics; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; PAZOPANIB;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FATIGUE; FEMALE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG INTERACTIONS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SULFONAMIDES;

EID: 84903814883     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2455-3     Document Type: Article

References (17)

1. Nieto M, Borregaard J, Ersboll J, ten Bosch GJ, van Zwieten-Boot B, Abadie E, Schellens JH, Pignatti F (2011) The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Clin Cancer Res 17:6608-6614
2. Verweij J, Sleijfer S (2013) Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother 14:929-935
3. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ (2009) Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1432-1439
4. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709-3714
5. Heath EI, Chiorean EG, Sweeney CJ, Hodge JP, Lager JJ, Forman K, Malburg L, Arumugham T, Dar MM, Suttle AB, Gainer SD, Lorusso P (2010) A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 88:818-823
6. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M (2007) Pharmacokineticpharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6:2012-2021 (Pubitemid 47052491)
7. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220-4227
8. Minocha M, Khurana V, Qin B, Pal D, Mitra AK (2012) Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib. Int J Pharm 436:127-134
9. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779-786
10. Inada-Inoue M, Ando Y, Kawada K, Mitsuma A, Sawaki M, Yokoyama T, Sunakawa Y, Ishida H, Araki K, Yamashita K, Mizuno K, Nagashima F, Takekura A, Nagamatsu K, Sasaki Y (2014) Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. Cancer Chemother Pharmacol 73:673-683
11. Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD (2010) An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 88:652-659
12. Sonpavde G, Hutson TE, Sternberg CN (2008) Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 17:253-261 (Pubitemid 351578205)
13. Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 98:1633-1640 (Pubitemid 351684684)
14. Ternant D, Paintaud G (2005) Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 5(Suppl 1):S37-S47 (Pubitemid 41243344)
15. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY (2013) Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica 43:443-453
16. Klumpen HJ, Samer CF, Mathijssen RH, Schellens JH, Gurney H (2011) Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 37:251-260
17. Suttle AB, Ball HA, Molimard M, Rajagopalan D, Swann S, Amado R, Pandite L (2010) Relationship between exposure to pazopanib and efficacy in patients with advanced renal cell carcinoma. J Clin Oncol 28:15 s (suppl; abstr 3048)